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(MS) have not been reached either in ﬁrst- or second-line. However, 
when split according to methylation status, there was a trend toward 
better TTP and MS in both ﬁrst- and second-line in p with methylated 
14-3-3σ. TTP in second-line in p with methylated 14-3-3σ has not been 
reached, while it was 10.8 months (m) for p with unmethylated 14-3-3σ 
(P=ns). TTP in second-line in p with methylated CHFR was 5.2 m but 
was not reached for p with unmethylated CHFR (P=0.05). 
Conclusions: Methylated 14-3-3σ can permit Cbl binding to mutant 
EGFR and predict longer-lasting response to erlotinib in p with EGFR 
mutations. The precise role of CHFR warrants further research. Com-
plete data will be presented. 
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Background: Qualitative and quantitative analysis of circulating 
DNA in blood is a promising non-invasive diagnostic and prognostic 
tool. Our aim was to study the association between the free amount 
in plasma of the catalytic subunit of telomerase (hTERT) and several 
clinical variables in advanced NSCLC patients.
Methods: We examined 451 NSCLC patients in stage IIIB and IV, 
treated with cisplatin and docetaxel. Blood samples were collected be-
fore chemotherapy, and circulating DNA was extracted from the serum 
using commercial adsorption columns. The amount of free hTERT in 
plasma was quantiﬁed by using RT-PCR.
Results: Median age was 61 years [35-82] and 84% were males. 99% 
had performance status 0-1. 84% were in stage IV and 16% in stage 
IIIB. The histological subtypes were: 32% squamous cell carcinoma, 
50% adenocarcinoma, 14% anaplastic large cell, and 4% undifferen-
tiated. 41% of the patients received second line chemotherapy. 1% 
achieved complete response (CR), 36% partial response (PR), 35% had 
stable disease (SD) and 28% progressive disease (PD). Median hTERT 
value was 4856 ng/ml; for patients in IIIB was 48 ng/ml [2-9648] and 
48 ng/ml [0.6-43735] in stage IV (p=0.75). There was not association 
between hTERT values and response to therapy. hTERT values were 
not related with the localization of the metastasis. Dividing the cohort 
in two sets according to hTERT median we found two signiﬁcantly dif-
ferent groups in terms of Overall Survival (OS) and Time To Progres-
sion (TTP). Patients with hTERT <48 ng/ml had a median TTP of 5.3 
months (m) [4.4-6.1] while for hTERT >48 ng/ml was 4.1 m [3.5-4.6], 
(p=0.0009). OS when hTERT <48 ng/ml was 10.1m [4.9-11.3] and for 
hTERT >48 ng/ml was 8.4 m [7.2-9.5], (p=0.01). In the multivariate 
analysis, hTERT was an independent predictive variable for TTP (HR 
1.39, CI 95% 1.1-1.7, p=0.002) and OS (HR 1.27, CI 95% 1.1-1.6, 
p=0.04).
Conclusions: In advanced NSCLC patients, the quantiﬁcation of free 
circulating hTERT in plasma is an affordable and valuable prognostic 
marker. High plasma hTERT levels are a poor prognostic indicator for 
TTP and OS.
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Background: EGFR has an extracellular ligand-binding domain that 
can be proteolitically cleaved from the cell surface and can be accu-
rately quantiﬁed in blood by ELISA. We have investigated the useful-
ness of plasma EGFR measurements as prognostic marker in advanced 
NSCLC.
Methods: The cohort consisted in 329 patients (p) with advanced 
NSCLC that received ﬁrst-line therapy with cisplatin and docetaxel. 
The concentration levels of the EGFR extracellular binding domain 
were determined by a sandwich quantitative ELISA in the baseline, 
before therapy.
Results: Median age was 61, range [39-80], 84% males, 100% cau-
casian, 68% stage IIIB and 32% IV and 99% PS 0-1. The histological 
subtypes were: 31% squamous cell carcinoma, 49% adenocarcinoma, 
15% large cell, and 5% undifferentiated. 181 p achieved complete 
response (CR), partial response (PR) or stable disease (SD) and 109 
p progressive disease (PD). Median patient’s plasma levels of EGFR 
were 32.4 ng/ml. There were not differences in p according to histolo-
gy, site of metastasis and ECOG. There were differences in response to 
therapy; CR+PR+SD p presented median EGFR of 31.97 ng/ml [13.2-
48.6] vs 30 ng/ml [16.9-46.8] in the PD group (p=0.024). Dividing the 
cohort in two sets according to EGFR median we found two signiﬁ-
cantly different groups in terms of Overall Survival (OS) and Time To 
Progression (TTP). Patients with EGFR<32.4 ng/ml had a median TTP 
of 3.9 months (m) [3.3-4.6] while for EGFR>32.4 ng/ml was 4.7 m 
[4.0-5.4], (p=0.024). OS when EGFR<32.4 ng/ml was 6.9 m [5.9-7.8] 
and for EGFR>32.4 ng/ml was 9.1 m [8.2-10.1], (p=0.038).
Conclusions: Patients with PD presented signiﬁcantly lower levels of 
serum EGFR than those patients with CR+PR+SD. There is a relation-
ship among lower EGFR concentration in serum with a worst prognosis 
in advanced NSCLC p in terms of TTP and OS.
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Background: Qualitative analysis of circulating DNA in blood is a 
promising non-invasive diagnostic and prognostic tool. Our aim was to 
